Products
Zigakibart Biosimilar Monoclonal Antibody (APRIL) for Research
Cat No.: GMP-Bios-INN-1476
Anti-TNFSF13/CD256/APRIL therapeutic antibody (Pre-made Zigakibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Zigakibart (development code BION-1301) is a humanized monoclonal antibody targeting APRIL (TNFSF13). It is developed by Chinook Therapeutics for IgA Nephropathy in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1476-1mg | 1mg | 3090 |
| GMP-Bios-INN-1476-10mg | 10mg | |
| GMP-Bios-INN-1476-100mg | 100mg | |
| GMP-Bios-INN-1476-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Zigakibart biosimilar, Whole mAb, Anti-TNFSF13/CD256/APRIL Antibody: Anti-APRIL/TNFSF13/CD256/Tumor necrosis factor ligand superfamily member 13 therapeutic antibody |
| INN Name | Zigakibart |
| Target | TNFSF13/CD256/APRIL |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Chinook Therapeutics |
| Conditions Approved | na |
| Conditions Active | IgA Nephropathy |
| Conditions Discontinued | Multiple myeloma |
| Production | na |
| Development Tech | na |
